An article in the Proceedings of the National Academy of Sciences (PNAS) Nexus journal* by Goel et al. describes studies in ...

A groundbreaking sickle cell disease treatment has been approved for use in the UK's National Health Service (NHS). The treatment offers patients with severe forms of the condition hope for a ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

Accumulation of clots causes some of the most severe symptoms of sickle cell disease, including strokes, kidney failure, ...

Drug-based therapy, starting with hydroxyurea ... The World Coalition on Sickle Cell Disease, launched in 2023, is an excellent example of the type of collaboration that will be needed to expand ...

It is believed around 1,700 people could be eligible for the treatment, while the NHS estimates around 50 people a year will ...

An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.

Global Blood Therapeutics (GBT) has persuaded the FDA to accept biomarker data from a phase III trial of sickle cell disease drug voxelotor as part of a filing for accelerated approval.

Clinical trials have shown that the one-time gene therapy, exagamglogene autotemcel (exa-cel), provides an effective cure in 96.6% of patients in addition to reducing pain completely and sickle cell ...